Zacks: Brokerages Expect XOMA Corp (XOMA) Will Announce Quarterly Sales of $830,000.00

Analysts predict that XOMA Corp (NASDAQ:XOMA) will post $830,000.00 in sales for the current quarter, Zacks reports. Two analysts have issued estimates for XOMA’s earnings, with estimates ranging from $660,000.00 to $1.00 million. XOMA posted sales of $36.18 million during the same quarter last year, which suggests a negative year over year growth rate of 97.7%. The company is expected to report its next earnings results on Monday, November 5th.

According to Zacks, analysts expect that XOMA will report full-year sales of $5.10 million for the current year, with estimates ranging from $4.20 million to $6.00 million. For the next financial year, analysts expect that the firm will post sales of $9.90 million, with estimates ranging from $6.00 million to $13.80 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for XOMA.

XOMA (NASDAQ:XOMA) last posted its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.03). XOMA had a return on equity of 379.39% and a net margin of 43.55%. The firm had revenue of $2.26 million during the quarter, compared to analysts’ expectations of $4.57 million.

Several research firms have issued reports on XOMA. Wedbush reiterated an “outperform” rating and issued a $33.00 target price on shares of XOMA in a research note on Wednesday, August 8th. Zacks Investment Research cut shares of XOMA from a “buy” rating to a “hold” rating in a research note on Saturday, July 21st. TheStreet upgraded shares of XOMA from a “d” rating to a “c-” rating in a research note on Tuesday, June 12th. S&P Equity Research lowered their target price on shares of XOMA from $18.74 to $16.26 in a research note on Tuesday, August 14th. Finally, ValuEngine cut shares of XOMA from a “hold” rating to a “sell” rating in a research note on Friday, September 7th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company’s stock. XOMA currently has a consensus rating of “Hold” and a consensus target price of $31.32.

NASDAQ XOMA opened at $17.80 on Friday. XOMA has a 1 year low of $15.35 and a 1 year high of $37.25. The company has a debt-to-equity ratio of 3.06, a quick ratio of 12.46 and a current ratio of 12.46. The company has a market capitalization of $139.14 million, a price-to-earnings ratio of 18.15 and a beta of 2.46.

Several large investors have recently modified their holdings of the company. BlackRock Inc. increased its holdings in shares of XOMA by 151.6% in the 2nd quarter. BlackRock Inc. now owns 448,856 shares of the biotechnology company’s stock worth $9,373,000 after buying an additional 270,437 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of XOMA by 70.4% in the 2nd quarter. Acadian Asset Management LLC now owns 96,051 shares of the biotechnology company’s stock worth $2,006,000 after buying an additional 39,672 shares during the last quarter. Northern Trust Corp increased its holdings in shares of XOMA by 308.6% in the 2nd quarter. Northern Trust Corp now owns 68,200 shares of the biotechnology company’s stock worth $1,424,000 after buying an additional 51,510 shares during the last quarter. Spark Investment Management LLC increased its holdings in shares of XOMA by 16.6% in the 2nd quarter. Spark Investment Management LLC now owns 52,100 shares of the biotechnology company’s stock worth $1,087,000 after buying an additional 7,400 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of XOMA by 50.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 35,661 shares of the biotechnology company’s stock worth $745,000 after buying an additional 12,002 shares during the last quarter. 43.60% of the stock is currently owned by hedge funds and other institutional investors.

About XOMA

XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.

Featured Article: Calculate Your Return on Investment (ROI)

Get a free copy of the Zacks research report on XOMA (XOMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for XOMA (NASDAQ:XOMA)

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply